

Cover Story
Guest Editorial
The initial reports of the near-miraculous benefits of CAR-T in pediatric acute lymphoblastic leukemia generated tremendous excitement—there was a Lazarus-like quality to these stories.
In Brief


Clinical Roundup


Drugs & Targets
Trending Stories
- U.S. News & World Report expands evaluation of outcomes in cancer subspecialties
- GOP-led Congress rejects Trump’s plans to gut medical research
Senate bill gives NIH a $400 million raise - Vinay Prasad falls from grace at FDA upon flunking Trump political purity test
MAHA leaders agree on one point: COVID was mishandled. Is that enough to run science-based agencies? - Cancer Research Institute announces 2025 recipients of cancer immunotherapy awards
- FY25 paylines drop to 4th percentile—a historic low—as NCI braces for Trump’s FY26 budget cuts
- USPSTF doesn’t lean right or left—it’s about data, not politics